- Home
- PAXS vs ORIC Comparison
PAXS vs ORIC Comparison
Compare PAXS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- ORIC
- Stock Information
- Founded
- PAXS 2021
- ORIC 2014
- Country
- PAXS United States
- ORIC United States
- Employees
- PAXS N/A
- ORIC N/A
- Industry
- PAXS Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- ORIC Health Care
- Exchange
- PAXS Nasdaq
- ORIC Nasdaq
- Market Cap
- PAXS 722.0M
- ORIC 735.3M
- IPO Year
- PAXS N/A
- ORIC 2020
- Fundamental
- Price
- PAXS $16.22
- ORIC $7.68
- Analyst Decision
- PAXS
- ORIC Strong Buy
- Analyst Count
- PAXS 0
- ORIC 10
- Target Price
- PAXS N/A
- ORIC $19.13
- AVG Volume (30 Days)
- PAXS 195.0K
- ORIC 1.6M
- Earning Date
- PAXS 01-01-0001
- ORIC 02-18-2025
- Dividend Yield
- PAXS 11.72%
- ORIC N/A
- EPS Growth
- PAXS N/A
- ORIC N/A
- EPS
- PAXS N/A
- ORIC N/A
- Revenue
- PAXS N/A
- ORIC N/A
- Revenue This Year
- PAXS N/A
- ORIC N/A
- Revenue Next Year
- PAXS N/A
- ORIC N/A
- P/E Ratio
- PAXS N/A
- ORIC N/A
- Revenue Growth
- PAXS N/A
- ORIC N/A
- 52 Week Low
- PAXS $12.57
- ORIC $6.33
- 52 Week High
- PAXS $15.93
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- PAXS 59.41
- ORIC 36.65
- Support Level
- PAXS $16.03
- ORIC $7.34
- Resistance Level
- PAXS $16.26
- ORIC $14.67
- Average True Range (ATR)
- PAXS 0.12
- ORIC 1.56
- MACD
- PAXS -0.01
- ORIC -0.45
- Stochastic Oscillator
- PAXS 56.41
- ORIC 4.64
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.